EXAMINING THE RELATIONSHIP BETWEEN SUBSCRIPTION LEVELS AND IPO RETURNS: EVIDENCE FROM THE INDIAN MAINBOARD MARKET
EPRA International Journal of Research & Development (IJRD) · 04.03.2026 · 1
DOI: 10.36713/epra26318 ↗Kurz gefasst
Fachartikel in der Zeitschrift EPRA International Journal of Research & Development (IJRD), online erschienen am 04.03.2026. Verfasst von Dr. Mayurkumar Vinubhai Dadresha.
Abstract (Originalsprache)
This study examines the relationship between subscription ratio and IPO listing performance in the Indian mainboard market for 2025. The study investigates the impact of investor demand on first-day returns using a sample of mainboard initial public offerings. The findings reveal a positive relationship, demonstrating that IPOs with higher subscription levels generally achieve better listing performance. The study also shows how subscription categories and issue size affect IPO results, with larger and more subscribed offers generally doing better. These insights contribute to understanding the demand-driven determinants of IPO performance and offer practical implications for investors, issuers, and market regulators. Keywords: IPO, Subscription Ratio, Listing Gain, Issue Price, Mainboard IPOs, India
Zitieren
APA
Dadresha, D. M. V. (2026). EXAMINING THE RELATIONSHIP BETWEEN SUBSCRIPTION LEVELS AND IPO RETURNS: EVIDENCE FROM THE INDIAN MAINBOARD MARKET. EPRA International Journal of Research & Development (IJRD), 1. https://doi.org/10.36713/epra26318
Vancouver
Dadresha DMV. EXAMINING THE RELATIONSHIP BETWEEN SUBSCRIPTION LEVELS AND IPO RETURNS: EVIDENCE FROM THE INDIAN MAINBOARD MARKET. EPRA International Journal of Research & Development (IJRD). 2026:1. doi:10.36713/epra26318
BibTeX
@article{Dadresha2026,
author = {Dadresha, Dr. Mayurkumar Vinubhai},
title = {EXAMINING THE RELATIONSHIP BETWEEN SUBSCRIPTION LEVELS AND IPO RETURNS: EVIDENCE FROM THE INDIAN MAINBOARD MARKET},
journal = {EPRA International Journal of Research & Development (IJRD)},
year = {2026},
pages = {1},
doi = {10.36713/epra26318}
}
EUVIMED